METHOD FOR PREDICTING PROGNOSIS OF RENAL CELL CARCINOMA

• Main Authors: ARAI ERI, TIAN YING, KANAI YAE
• Format: Patent
• Language: English; Korean
• Published: 14.10.2019
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPIRITS; VINEGAR; WINE

간편하고 매우 높은 감도 및 특이성을 가진 신장 세포암의 예후 불량 리스크를 검출하기 위한 방법을 제공하는 것을 목적으로 하여 정상 신장 조직, 신장 세포암 환자 유래의 비암 조직 및 신장 세포암에 대해서 메틸롬 분석을 행했다. 그 결과, FAM150A, GRM6, ZNF540, ZFP42, ZNF154, RIMS4, PCDHAC1, KHDRBS2, ASCL2, KCNQ1, PRAC, WNT3A, TRH, FAM78A, ZNF671, SLC13A5 및 NKZ6-2 유전자 중 적어도 하나의 CpG 사이트에서의 DNA 메틸화 레벨을 검출함으로써 신장 세포암의 예후 불량 리스크를 검출할 수 있는 것을 발견했다. In order to provide a method for detecting an unfavorable prognostic risk of renal cell carcinoma easily with quite high sensitivity and specificity, a methylome analysis was performed on normal renal tissues, and non-cancerous tissues and renal cell carcinomas derived from patients with renal cell carcinomas. The result revealed that it was possible to detect an unfavorable prognostic risk of renal cell carcinoma by detecting a DNA methylation level at at least one CpG site of FAM150A, GRM6, ZNF540, ZFP42, ZNF154, RIMS4, PCDHAC1, KHDRBS2, ASCL2, KCNQ1, PRAC, WNT3A, TRH, FAM78A, ZNF671, SLC13A5, and NKX6-2 genes.